Vita Life Sciences - Public Comps and Valuation Multiples

Vita Life Sciences Overview

About Vita Life Sciences

Vita Life Sciences Ltd is an Australian based pharmaceutical and healthcare company involved in formulating, packaging, sales, and distribution of vitamins and supplements. The company produces a wide range of premium supplements, vitamins, minerals, herbs and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, Herbs of Gold brands throughout Asia-Pacific region. The company has four reportable segments which include The Australia segment comprises of sale of Herbs of Gold range in Australia and exports into China. The Singapore and Malaysia segment, comprise of Vitahealth and Herbs of Gold range in both countries The other market segment comprises of Vitahealth ranges.

Founded

1986

HQ

Employees

n/a

Website

vitalifesciences.com

Sectors

Nutraceuticals & Cosmeceuticals

Financials

Last FY Revenue $52.1M

Last FY EBITDA $8.8M

EV

$75.9M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Vita Life Sciences Financials

See Vita Life Sciences valuation multiples based on analyst estimates

Vita Life Sciences P&L

In the most recent fiscal year, Vita Life Sciences reported revenue of $52.1M and EBITDA of $8.8M.

Vita Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Vita Life Sciences valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$52.1M	XXX	XXX	XXX
Gross Profit	XXX	$31.0M	XXX	XXX	XXX
Gross Margin	XXX	59%	XXX	XXX	XXX
EBITDA	XXX	$8.8M	XXX	XXX	XXX
EBITDA Margin	XXX	17%	XXX	XXX	XXX
EBIT	XXX	$7.6M	XXX	XXX	XXX
EBIT Margin	XXX	15%	XXX	XXX	XXX
Net Profit	XXX	$5.8M	XXX	XXX	XXX
Net Margin	XXX	11%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Vita Life Sciences including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Vita Life Sciences achieved $52.1M in revenue and $8.8M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$52.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$31.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	59.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$8.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	16.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$7.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	14.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$5.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	11.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Vita Life Sciences

This financial data table provides comprehensive performance metrics for Vita Life Sciences, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Vita Life Sciences reported $52.1M in total revenue.
Fiscal year EBITDA was $8.8M.
The company maintained a gross profit margin of 59.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 16.9%.
Net profit margin reached 11.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Vita Life Sciences. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Vita Life Sciences Stock Performance

Vita Life Sciences has current market cap of AUD 143M (or $93.7M), and EV of AUD 116M (or $75.9M).

Market Cap Evolution

Vita Life Sciences Stock Data

As of September 19, 2025, Vita Life Sciences's stock price is AUD 3 (or $2).

See Vita Life Sciences trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$75.9M	$93.7M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Vita Life Sciences Valuation Multiples

Vita Life Sciences's trades at 1.5x EV/Revenue multiple, and 8.6x EV/EBITDA.

See valuation multiples for Vita Life Sciences and 15K+ public comps

Vita Life Sciences Financial Valuation Multiples

As of September 19, 2025, Vita Life Sciences has market cap of $93.7M and EV of $75.9M.

Equity research analysts estimate Vita Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vita Life Sciences's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$93.7M	XXX	$93.7M	XXX	XXX	XXX
EV (current)	$75.9M	XXX	$75.9M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	1.5x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	8.6x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	9.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	16.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	19.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vita Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Vita Life Sciences Margins & Growth Rates

Vita Life Sciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Vita Life Sciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vita Life Sciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Vita Life Sciences and other 15K+ public comps

Vita Life Sciences Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	17%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	17%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	45%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial